Browse by Series:

FDA Approval of Second Dosing Schedule of Nivolumab

Gina Columbus
Published: Tuesday, Mar 06, 2018



Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.

The FDA has approved a second dosing schedule for the PD-1 inhibitor nivolumab across all of the PD-1 inhibitor's monotherapy indications. This now allows physicians to prescribe the new dosing schedule of 480 mg of nivolumab every 4 weeks.

Nivolumab is currently approved as a single agent for advanced melanoma, advanced non-small cell lung cancer, advanced renal cell carcinoma, metastatic urothelial carcinoma, Hodgkin lymphoma, and advanced head and neck squamous cell carcinoma.

For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.
SELECTED
LANGUAGE
Slider Left
Slider Right


Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.

The FDA has approved a second dosing schedule for the PD-1 inhibitor nivolumab across all of the PD-1 inhibitor's monotherapy indications. This now allows physicians to prescribe the new dosing schedule of 480 mg of nivolumab every 4 weeks.

Nivolumab is currently approved as a single agent for advanced melanoma, advanced non-small cell lung cancer, advanced renal cell carcinoma, metastatic urothelial carcinoma, Hodgkin lymphoma, and advanced head and neck squamous cell carcinoma.

For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x